LifeVantage reports Q1 adjusted EPS 18c, two estimates 19c

Reports Q1 revenue $47.6M, two estimates $54.74M. “The first quarter marked a pivotal milestone for LifeVantage (LFVN) as we focused on closing our strategic acquisition of LoveBiome, positioning us as a leader at the intersection of two rapidly expanding wellness markets: natural GLP-1 activation and microbiome health,” said Steve Fife, president and CEO of LifeVantage. “We’re seeing several encouraging trends that should drive accelerating growth as we scale our combined operations and realize the full benefits of our strategic investments. The integration of LoveBiome’s passionate consultant community along with their flagship P84 product is already exceeding expectations and momentum is building across our business. With a comprehensive wellness ecosystem that addresses multiple aspects of human health through scientifically validated activation technologies, we are uniquely positioned to serve the evolving needs of consumers worldwide.”